

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8273229

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	SCIODERM, INC.	11/07/2023
RECEIVING PARTY DATA		
Name:	PARADIGM THERAPEUTICS, INC.	
Street Address:	465 WEST COLEMAN BLVD, SUITE 202	
City:	MT. PLEASANT	
State/Country:	SOUTH CAROLINA	
Postal Code:	29464	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Patent Number:	9339492
CORRESPONDENCE DATA		
Fax Number:	(202)371-2540	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	2023712600	
Email:	hmagann@sternekessler.com, HBALL@sternekessler.com, DSTERLING@sternekessler.com	
Correspondent Name:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.	
Address Line 1:	1101 K STREET NW, 10TH FLOOR	
Address Line 4:	WASHINGTON, D.C. 20005	
ATTORNEY DOCKET NUMBER:	5360.0020006	
NAME OF SUBMITTER:	DEBORAH A. STERLING, REG. NO. 62,732	
SIGNATURE:	/Deborah A. Sterling/	
DATE SIGNED:	11/13/2023	
Total Attachments: 2		
source=Assignment-Scioderm-Paradigm-5360-0020006#page1.tif		
source=Assignment-Scioderm-Paradigm-5360-0020006#page2.tif		

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration, receipt of which is hereby acknowledged,

Scioderm, Inc. (hereafter referred to as "Assignor"), a corporation organized and existing under the laws of Delaware and having an office and place of business at 4601 Creekstone Drive, Suite 160, Durham, North Carolina 27703, hereby sells and assigns to

Paradigm Therapeutics, Inc., a corporation formed under the laws of South Carolina, having an office and place of business at 465 West Coleman Blvd, Suite 202, Mt. Pleasant, South Carolina 29464 (hereafter referred to as "Assignee"), its entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), and throughout the world, including the right to sue for past infringement and to collect for all past, present and future damages,

(a) U.S. Patent Application No. 14/789,173, entitled **Methods of Treating Psoriasis Using Allantoin**, filed on July 1, 2015, which issued as U.S. Patent No. 9,339,492; issued on May 17, 2016; and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The Assignor agrees to execute all papers necessary in connection with the applications and Letters Patents as above, and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding applications thereof, and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

The Assignor agrees to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, patent enforcement action (judicial or otherwise) related to the applications or Letters Patents or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application thereof and to cooperate with the Assignee at Assignee's expense in every reasonable way possible in obtaining evidence and going forward with such judicial or administrative proceeding.

The Assignor hereby represents that Assignor has full right and authority to convey the entire interest herein assigned, and that Assignor has not executed, and will not execute, any agreement in conflict therewith.

The Assignor hereby grants the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification regarding the patent and patent application so identified above in part (a) that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned Assignor hereby represents that the Assignor understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are legal representatives of, and attorneys for, the Assignee, and are NOT the legal representatives of, and attorneys for, the Assignor.

SIGNED on behalf of the said ASSIGNOR,

Scioderm, Inc.

By: Ellen Rosenberg
 Name: Ellen Rosenberg
 Title: Director
 Date: November 7, 2023

SIGNED on behalf of the said ASSIGNEE,

Paradigm Therapeutics, Inc.

By: Robert R. Raw
 Name: ROBERT RAW
 Title: CEO
 Date: Nov 7, 2023